Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.
Latest from Andrew McConaghie
The rare disease blockbuster has stumbled in a key Phase III study, although Argenx still has plenty of other pipeline opportunities.
Having worked in stealth on its predictive computational R&D models, PsiThera has emerged to develop oral versions of blockbuster drug targets in inflammation and immunology.
After a solid but modest launch in acute lymphoblastic leukemia, Autolus sees an opportunity for its CAR-T in autoimmune disease, starting with lupus nephritis.
WVE-007 could be a "powerful disruptor" to the existing obesity market, says the company, which is set to raise $250m to fund its Phase II studies.
The base-editing company’s risto-cel may have an efficacy edge over Vertex’s Casgevy, but both will be held back by safety concerns about chemotherapy preconditioning for patients.
Janux wowed last year with first data from its ‘masked’ T-cell engager, JANX007, but investors have been spooked by newly updated results for the product. Analysts, however, still think it can compete with rivals from Amgen and J&J.